Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer DOI Creative Commons

Luohang Ni,

Jianing Xu,

Quanpeng Li

et al.

Cancer Management and Research, Journal Year: 2024, Volume and Issue: Volume 16, P. 941 - 963

Published: July 1, 2024

Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides comprehensive overview of advances preclinical clinical studies BTC. We explore potential immune checkpoint inhibitors reshaping management Despite disappointing results thus far, ongoing trials are investigating combination with other modalities. Furthermore, research on tumor microenvironment unveiled novel targets immunotherapeutic interventions. By understanding current state highlighting future directions, this aims to fuel further exploration ultimately improve patient outcomes disease.

Language: Английский

Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy DOI Open Access
Joo Dong Park, Ha Eun Shin,

Y. An

et al.

Annals of Laboratory Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Joo Dong Park, M.S., Ha Eun Shin, Ph.D., Yeon Su An, B.S., Hye Jung Jang, Juwon Se-Na Kim, Chun Gwon and Wooram Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0380

Citations

2
Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment DOI Open Access

Shuxi Yao,

Xinyue Liu,

Yanqi Feng

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 9101 - 9101

Published: Aug. 22, 2024

Non-small cell lung cancer (NSCLC) is characterized by several molecular alterations that contribute to its development and progression. These include the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), human 2 (HER2), mesenchymal-epithelial transition (c-MET). Among these, hepatocyte (HGF)/c-MET signaling pathway plays a crucial role in NSCLC. In spite of this, involvement HGF/c-MET axis remodeling tumor microenvironment (TME) remains relatively unexplored. This review explores biological functions both normal cancerous cells, examining multifaceted roles NSCLC microenvironment, including proliferation, migration invasion, angiogenesis, immune evasion. Furthermore, we summarize current progress clinical applications MET-targeted therapies discuss future research directions, such as novel MET inhibitors potential combination immunotherapy.

Language: Английский

Citations

5
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy DOI Open Access
Neda Dadgar, Arun Kumar Arunachalam, Hanna Hong

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(18), P. 3232 - 3232

Published: Sept. 23, 2024

Cholangiocarcinoma (CCA) is a rare and aggressive malignancy originating from the bile ducts, with poor prognosis limited treatment options. Traditional therapies, such as surgery, chemotherapy, radiation, have shown efficacy, especially in advanced cases. Recent advancements immunotherapy, particularly T cell-based therapies like chimeric antigen receptor (CAR T) cells, tumor-infiltrating lymphocytes (TILs), cell (TCR)-based opened new avenues for improving outcomes CCA. This review provides comprehensive overview of current state CCA, focusing on CAR therapy. It highlights key challenges, including complex tumor microenvironment immune evasion mechanisms, progress made preclinical clinical trials. The also discusses ongoing trials targeting specific CCA antigens, MUC1, EGFR, CD133, evolving role precision immunotherapy enhancing outcomes. Despite significant progress, further research needed to optimize these solid tumors By summarizing most recent results future directions, this underscores promising potential revolutionizing treatment.

Language: Английский

Citations

4
Phage display for discovery of anticancer antibodies DOI Creative Commons

Polina V Istomina,

Andrey A. Gorchakov,

Chatchanok Paoin

et al.

New Biotechnology, Journal Year: 2024, Volume and Issue: 83, P. 205 - 218

Published: Aug. 24, 2024

Antibodies and antibody-based immunotherapeutics are the mainstays of cancer immunotherapy. Expanding repertoire cancer-specific cancer-associated epitopes targetable with antibodies represents an important area research. Phage display is a powerful approach allowing use diverse antibody libraries to be screened for binding wide range targets. In this review, we summarize basics phage technology highlight advances in anticancer identification modification via platform. Finally, describe display-derived monoclonal that have been approved date or clinical development.

Language: Английский

Citations

3
Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications DOI Open Access
Angela Dalia Ricci, Alessandro Rizzo,

Annalisa Schirizzi

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(20), P. 3542 - 3542

Published: Oct. 20, 2024

Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant tumor with poor prognosis, are limited. Recent developments in immunotherapy and immune checkpoint inhibitors (ICIs) have offered new hope treating iCCA. However, several issues remain, including the identification of reliable biomarkers response to ICIs immune-based combinations. Tumor microenvironment (TIME) these hepatobiliary tumors has been evaluated is under assessment this setting order boost efficacy convert immunologically "cold" "hot" tumors. Herein, review TIME ICCA its critical function immunotherapy. Moreover, paper also discusses potential avenues future research, novel targets emerging treatment plans aimed increase effectiveness survival rates iCCA patients.

Language: Английский

Citations

2
Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer DOI Creative Commons

Luohang Ni,

Jianing Xu,

Quanpeng Li

et al.

Cancer Management and Research, Journal Year: 2024, Volume and Issue: Volume 16, P. 941 - 963

Published: July 1, 2024

Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides comprehensive overview of advances preclinical clinical studies BTC. We explore potential immune checkpoint inhibitors reshaping management Despite disappointing results thus far, ongoing trials are investigating combination with other modalities. Furthermore, research on tumor microenvironment unveiled novel targets immunotherapeutic interventions. By understanding current state highlighting future directions, this aims to fuel further exploration ultimately improve patient outcomes disease.

Language: Английский

Citations

1